Medicaid chiefs from red and blue states are urging Congress to stem the cost of revolutionary new drugs for hepatitis C, cancer, and other diseases. Read More
Safety Net Hospitals for Pharmaceutical Access (SNHPA) has joined the Campaign for Sustainable Rx Pricing (CSRxP), a broad-based coalition concerned about the skyrocketing cost of prescription medicines. Read More
Some of the nation’s hospitals are seriously ticked off at Genentech, the San Francisco biotech firm, for implementing a stealth price hike for three critical cancer drugs. Read More
What the study should have asked is whether or not the price Gilead set for the therapy is appropriate for all patients–even asymptomatic patients–and whether or not such a large portion of potential societal value should accrue to one company. Read More
A great deal of analysis has been published on the causes of the health care spending slowdown system-wide — including in the pages of Health Affairs. Read More
Boehringer Ingelheim GmbH priced its new treatment for a deadly lung-scarring disease at $96,000 a year, just higher than Roche Holding AG’s (ROG) competing product. Read More
Some patients are paying sky-high prices for ‘specialty medications’ when cheaper options exist, a team of researchers has found. Read More
Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers. Read More
Harvoni’s launch brought new howls about price gouging from insurers and a broad coalition of health care groups. They warn that the drugs, no matter how revolutionary, are ultimately unaffordable given the estimated 3 million Americans who may be infected with hepatitis C. Read More
According to a recent survey from the Kaiser Family Foundation, almost every state Medicaid plan is concerned about the rising cost of specialty drugs -- specifically Sovaldi. Sovaldi is a hepatitis c drug from Gilead Sciences which costs $1,000 a pill, or $84,000 for a 12-week treatment—prices which the plans have balked at. Read More
On the day that Gilead introduced its new $94,500 hepatitis C drug, Harvoni, Gilead Vice President of Investor Relations Patrick O'Brien went into full spin mode, telling Politico (subscription required) that Harvoni is a bargain compared to Gilead's other hep C drug, the $84,000 Sovaldi. Read More
Perhaps no company has done as much as Gilead to propel the issue of high drug prices onto center stage or to lay bare the pharmaceutical industry’s approach to pricing new drugs. Read More